Fevipiprant, a selective prostaglandin D receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. (2019)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jaci.2019.02.015

PubMed Identifier: 30825466

Publication URI: http://europepmc.org/abstract/MED/30825466

Type: Journal Article/Review

Volume: 143

Parent Publication: The Journal of allergy and clinical immunology

Issue: 6

ISSN: 0091-6749